Immunotherapy with fusions of glioma cells, glioma initiating cells,and dendritic cells for patients with malignant glioma - GLIM-FDG

Akasaki Yasuharu0 个研究点目标入组 50 人开始时间: 2019年10月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)A patient who requires a sugery against brain tumor regarded as malignant glioma (WHO grade 2 or 3 or 4) on an imaging examnination(CT or MRI) of brain.
•2) A patient who is 15 year to under 75 year, at the time of entry for this trial.
•3)A patient who is able to undergo a collection of peripheral blood mononuclear cells(PBMC) using an apehresis system.
•4)A patient who preserves function of major organs, such as hart, liver, kidny, and bone marrow etc, with satisfying the standerds below.
•5)A patient who is estimated 2 or less the Performance status(PS) grade.
•6)A patient who is expected to be alive for 3 months and more.
•7)A patient who has no other cancer.

•1) A patient who has an allergy against biological products
•2) A patient who has past or current history of autoimmune disease
•3) A patient who is a HBV carrier, testing positive for antibodies of HCV, HIV, and HTLV.
•4) A patient who has an immune deficiency for some reasons.
•5) A patient who is taking steroids for long time, and is hard to stop them.
•6) A patient who has a sever infection.
•7) A patient who has a sever respiratory disease(Hugh-Jones Class 3 or more).
•8) A patient who has a sever hart disease(NYHA Class 3 or more).
•9) A patient who has uncontrolable diabetes.
•10) A pregnant or possibility of pregnant woman, and a breastfeeder.
•11) A patient who has been registered in other clinical trial.
•12) A patient who is judged as unsuitable subject for this trial in some reasons.

发起方

Akasaki Yasuharu